Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

Fig. 2

Comparative inhibitor responsiveness between endometrial cancer cell line groups are shown in Table 2. The figures derived by comparing average IC50s between the groups for each inhibitor alone and in combination a Comparative responsiveness of pictilisib in EC cell line groups, b Comparative responsiveness of apitolisib in EC cell line groups, c Comparative responsiveness of cobimetinib in EC cell line groups. P < 0.05 is statistically significant

Back to article page
\